MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.

She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.

MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.

The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.

How Metal Objects Interact with MRI Fields?

On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."

The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.

This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.

A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.

These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.

Preventing MRI-Related Incidents

Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:

• Patients are interrogated about implants, recent surgery or exposures at work related to metals.
• Radiologists sometimes use handheld metal detectors to search for hidden items.
• People who work with metal, like welders or machinists, will need additional testing to detect microscopic metal fragments within soft tissues or eyes.

The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.

It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.

In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.

This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.

People who have had COVID-19 may be more likely to need allergy medications months after initial infection, according to a large Japanese study.

The study analysed health records of more than 778,000 people, suggesting that the effects of COVID-19 may extend beyond the respiratory illness and could be related to immune function after infection.

The study, published in BMC Public Health, examined whether people diagnosed with COVID-19 were more likely to receive new prescriptions for allergy medications than individuals who had not contracted the infection.

Researchers analysed health insurance records for 778,362 people diagnosed with COVID-19 and compared them to a group of individuals who were not infected.

They tracked new prescriptions for four categories of allergy medications, including antihistamines, leukotriene receptor antagonists, eye drops for allergic conditions and nasal sprays used to treat rhinitis.

Over a median follow-up period of seven months, people who had COVID-19 were 21% more likely to receive a new prescription for allergy medication than those in the comparison group.

The association was stronger among older adults and people with pre-existing health conditions. The researchers also found that elevated prescription rates remained detectable beyond one year after infection in a few high-risk groups.

However, the study merely identifies an association between infection and subsequent use of allergy medications and does not establish a causal link.

How Could COVID-19 Affect Allergy Risk?

Also read: XFG Variant In Spain: COVID-19 Cases Rise Amid Respiratory Infection Surge

Allergies occur when the immune system overreacts to substances that are usually harmless, like pollen, dust mites or certain foods. This response can trigger symptoms including sneezing, itching, a runny nose, skin rashes and watery eyes.

Antihistamines work by blocking the effects of histamine, a chemical that is released during these allergic reactions. Leukotriene receptor antagonists target inflammatory elements involved in conditions like asthma and allergic rhinitis.

Researchers believe that infections caused by respiratory viruses can sometimes alter immune responses, affecting processes involved in allergic inflammation.

COVID-19 has been known to cause changes in immune system that can last beyond the initial illness. Damage to the lining of the respiratory tract and changes in inflammatory response could influence how the body responds to allergens.

However, these mechanisms were not directly established by the Japanese study. The researchers used prescription records rather than laboratory tests to confirm newly developed allergic diseases.

Who Is At Greater Risk?

Also read: Long COVID: Mouth And Lung Bacteria May Offer Clues

The association between COVID-19 and new allergy medication prescriptions was more pronounced among people aged 65 and older.

In this group, the rate of new prescriptions was 33% higher among those who had contracted COVID-19 than among their matched counterparts. Among people with substantial pre-existing illnesses, the rate was 35% higher.

The researchers also found that it lasted more than one year in these groups, although it gradually weakened over time.

These findings suggest that older adults and people managing multiple health conditions may warrant closer attention to new symptoms following COVID-19.

The study's large sample size provides useful evidence about patterns in allergy medication use after COVID-19. But a prescription does not always mean a new allergy diagnosis. Some medications included in the analysis can be prescribed for conditions other than allergies, and people recovering from COVID-19 may have more opportunities to consult doctors or receive prescriptions.

The findings also come from Japan and may not apply equally to populations with different healthcare systems, demographics or patterns of medication use. Further research is needed to determine whether COVID-19 contributes to the development of new allergic conditions.

Pope Leo XIV recently underwent lung cancer surgery to have the lower lobe of his right lung removed. According to the Vatican, the 71-year-old pontiff's recovery is on track. But doctors are awaiting further test results to determine whether he needs further treatment. The pope has resumed eating, walking and celebrating Mass but he is not fit to take a trip just yet.

The pope underwent surgery at Rome's Gemelli Hospital on October 13 after doctors identified a suspicious lung nodule. The procedure confirmed lung adenocarcinoma, the most common type of lung cancer, and surgeons removed the lower lobe of his right lung.

In a update on October 14, the pope's personal physician, Dr Luigi Carbone, and thoracic surgeon Professor Stefano Margaritora said, "The Holy Father underwent respiratory physiotherapy and has begun walking in his room. He resumed his regular diet and had breakfast and lunch." They added, "Recovery is proceeding as planned."

Blood tests and a chest X-ray indicated that the pope was recovering normally after the operation. He also celebrated Mass with his secretaries in a private hospital chapel.

However, doctors have not yet disclosed whether the cancer has spread to the lymph nodes or other parts of the body. That will help determine if further treatment is needed.

Surgery For Lung Lobe

The lungs are divided into sections called lobes. The right lung has three lobes, while the left lung has two. When cancer is confined to a particular area, surgeons may remove the affected lobe in an operation called a lobectomy.

The procedure aims to remove the tumour along with surrounding tissue to reduce the likelihood of cancer remaining in the lung. Nearby lymph nodes may also be removed and examined to check whether cancer cells have spread.

Pope Leo underwent surgery assisted by video, a minimally invasive technique that uses a camera and small surgical incisions to operate inside the chest.

Dr PierCarlo Gentile, head of radiation oncology at Rome's San Pietro Fatebenefratelli Hospital, told The Associated Press that this type of surgery typically requires around 15 to 20 days of recovery. He also said that in this case postoperative complications, including infections, is rare.

Also read: Pope Leo XIV, Diagnosed With Lung Cancer, Undergoes Surgery As His Brother Battles Relapsed Multiple Myeloma

Recovery After Lung Lobe Removal

After a lobectomy, the remaining lung tissue can help compensate for some of the lost lung capacity. However, recovery varies depending on a person's age, overall health, lung function before surgery and the extent of the operation.

In the initial days, patients are encouraged to get out of bed and walk as soon as medically appropriate. Early movement helps reduce the risk of blood clots and other complications associated with prolonged bed rest.

Respiratory physiotherapy is also a part of recovery. Breathing exercises help patients expand their remaining lung tissue, improve ventilation and clear secretions from the airways. Some patients may also need oxygen support temporarily.

Pain management, proper nutrition and slow and gradual increases in physical activity are important. Breathlessness and fatigue can persist for weeks, and full recovery may take longer than the initial hospital stay.

Although the remaining lung tissue can adapt, it does not mean lung capacity automatically returns to its previous level. The extent of recovery depends on the individual's baseline respiratory health and how much functioning lung tissue remains.

Also read: Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?

Additional Cancer Treatment

The need for additional treatment for Pope Leo will depend on the final results, including the tumour's size and whether cancer cells are present in the lymph nodes.

If the cancer is localised and has been completely removed, surgery may be sufficient in some cases. If tests show that the disease has spread or carries features associated with a higher risk of recurrence, doctors may consider chemotherapy, immunotherapy or targeted therapy, depending on the tumour's characteristics.

Dr Stephen Liu, a lung cancer expert at Georgetown University's Lombardi Comprehensive Cancer Center who is not involved in the pope's care, told The Associated Press, "While we know the diagnosis, we now need to know the stage."

The US Food and Drug Administration (FDA) recently expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln), a bladder cancer treatment, to include adults with high-grade papillary bladder cancer that has not responded to Bacillus Calmette-Guérin (BCG) therapy.

The decision provides a new treatment option for patients whose cancer persists or returns despite standard immunotherapy.

The approval specifically covers BCG-unresponsive, high-grade papillary-only non-muscle-invasive bladder cancer (NMIBC). Anktiva was already approved in April 2024 for certain patients with BCG-unresponsive NMIBC involving carcinoma in situ, with or without papillary tumours.

The latest development is significant because patients with high-grade papillary-only disease previously had fewer approved bladder-preserving treatment options after BCG failed.

The FDA based its decision on evidence supporting Anktiva's earlier approval, alongside scientific similarities between the two forms of bladder cancer.

“We listen to patients, clinicians, and researchers, and we act when the science supports a new approach,” said R. Angelo de Claro, MD, director of the FDA's Oncology Center of Excellence.

“For Anktiva, our review of the similarities between these cancers allowed us to build on the results in patients with CIS and expand treatment options for people with high-grade papillary tumors alone. This approach may also help guide the development of future treatments.”

What Is BCG-Unresponsive Bladder Cancer?

Also read: Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?

BCG is a form of immunotherapy used to treat high-risk non-muscle-invasive bladder cancer. Although the name comes from a bacterium originally used in tuberculosis vaccination, BCG is administered directly into the bladder to initiate an immune response against cancer cells.

NMIBC refers to bladder cancer that has not grown into the muscle layer of the bladder wall. Treatment often involves removing visible tumours through a procedure called transurethral resection of bladder tumour (TURBT), followed by BCG therapy to destroy remaining cancer cells and reduce the risk of recurrence.

However, some cancers return despite treatment. These are described as BCG-unresponsive, and patients may need alternative therapies or surgery to remove the bladder.

More About Anktiva

Also read: Can A Blood Test Predict Childhood Cancer Years Before Diagnosis? Study Gives Clues

Anktiva is an interleukin-15 receptor agonist, a type of immunotherapy designed to strengthen the body's immune response against cancer.

It activates and expands immune cells, including natural killer cells and T cells, which help recognise and attack abnormal cells. When administered with BCG, Anktiva provides an additional immune stimulus to help the body fight cancer within the bladder.

The medicine is delivered directly into the bladder through a catheter, a procedure known as intravesical instillation. This allows treatment to act locally rather than being administered through an intravenous infusion.

Treatment begins with weekly doses for six weeks. Depending on the patient's response, additional induction and maintenance treatment may be given, with the overall treatment period extending up to 37 months.

FDA's Approval For Anktiva

The FDA's original approval was supported by the QUILT-3.032 clinical trial, which included 77 adults with BCG-unresponsive, high-risk NMIBC involving CIS, with or without papillary tumours.

The study found a complete response rate of 62%. This means that no high-grade cancer was detected during the relevant assessments. Among patients who achieved a complete response, 58% maintained it for at least 12 months, while 40% maintained it for at least 24 months.

For the expanded approval, the FDA considered these findings alongside laboratory evidence indicating that CIS and high-grade papillary-only tumours share key biological features. Both can recur or progress when BCG treatment fails.

The agency concluded that the earlier evidence of effectiveness could be applied to patients with high-grade papillary-only disease.